References

9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026

2026 · External reference

10.2337/dci22-0034 · 2022 · Admitted local publication

Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials

10.2337/dc24-1533 · 2025 · External reference

Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist

10.1007/s13300-024-01554-1 · 2024 · External reference

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

10.1016/s0140-6736(26)00202-3 · 2026 · External reference

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial

10.1016/s0140-6736(26)00800-7 · 2026 · External reference

Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes

10.1056/nejmoa2505669 · 2025 · External reference

Orforglipron added to titrated insulin glargine in type 2 diabetes: the ACHIEVE-5 randomized clinical trial

10.1001/jama.2026.9512 · 2026 · External reference

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

10.1016/s0140-6736(25)02165-8 · 2026 · External reference

Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment

10.1056/nejmoa2511774 · 2025 · External reference

Basal insulin and cardiovascular and other outcomes in dysglycemia

10.1056/nejmoa1203858 · 2012 · External reference

Pharmacokinetic bioequivalence of orforglipron tablets and capsules in healthy participants with obesity or overweight

10.1111/dom.70783 · 2026 · External reference

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

10.2337/diacare.26.11.3080 · 2003 · External reference

A proportional hazards model for the subdistribution of a competing risk

10.1080/01621459.1999.10474144 · 1999 · External reference

Estimating glomerular filtration rate from serum creatinine and cystatin C

10.1056/nejmoa1114248 · 2012 · External reference

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

10.1016/s2213-8587(24)00271-7 · 2025 · External reference

Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis

10.1111/dom.14443 · 2021 · External reference

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

10.1016/s0140-6736(19)31150-x · 2019 · External reference

Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: results from the SOUL randomized trial

10.2337/dc25-1080 · 2026 · External reference

Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes

10.1056/nejmoa2403347 · 2024 · External reference

Mechanistic effects of semaglutide on kidney disease in type 2 diabetes: the REMODEL trial

2025 · External reference

Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients

10.1016/j.jacc.2021.01.027 · 2021 · External reference

Remnant cholesterol reduction for atherosclerotic cardiovascular disease prevention: modelling in the Copenhagen General Population Study

10.1093/eurjpc/zwaf203 · 2025 · External reference

Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis

10.1053/j.gastro.2025.06.003 · 2025 · External reference

Hepatic safety of orforglipron in adults with obesity or overweight and/or type 2 diabetes: a pooled analysis of the orforglipron phase 3 clinical trials

10.1111/dom.71032 · 2026 · External reference

Pancreatic safety of incretin-based drugs—FDA and EMA assessment

10.1056/nejmp1314078 · 2014 · External reference

Use and misuse of composite endpoints in randomised clinical trials

10.1136/heartjnl-2025-326545 · 2026 · External reference